CKD Bio Corp
CKD Bio Corp is a South Korean pharmaceutical company that develops and commercializes drugs, primarily in the nephrology and urology therapeutic areas.
Business. CKD Bio Corp (063160.KS) is a South Korean pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the Korea Exchange (KRX) under the ticker symbol 063160.KS. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CKD Bio Corp (063160.KS) is a South Korean pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the Korea Exchange (KRX) under the ticker symbol 063160.KS. Specific details regarding operating segments or geographic revenue breakdowns are not available.
CKD Bio Corp has a market price of 17,930 KRW and a market capitalization of 98,363,244,870 KRW, with a price-to-earnings ratio of 34.74 and a price-to-book ratio of 0.78. The company's liquidity position is characterized by a current ratio of 1.16 and a negative net cash position after subtracting total debt, indicating a medium liquidity risk. The company's debt-to-equity ratio is 1.18, suggesting a moderate reliance on debt financing.
In terms of profitability, CKD Bio Corp has a return on equity of 2.25% and a return on assets of 0.95%, both of which are below the typical thresholds for pharmaceutical companies, indicating a relatively weak performance in generating returns from equity and assets. The company's gross profit margin is 20.3%, and its operating margin is 6.99%, which are key metrics for assessing profitability in the pharmaceutical industry.
CKD Bio Corp's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is primarily derived from its pharmaceutical products, with no significant diversification across therapeutic areas or geographic regions. This concentration increases the company's exposure to market-specific risks and regulatory changes in its primary operating region.
The company's growth trajectory is modest, with no disclosed revenue growth rates or future projections. The company's operating cash flow is 3,502,109,750 KRW, and its free cash flow is 5,173,329,070 KRW, indicating a positive cash flow generation capability. However, the company's capital expenditure is negative, suggesting a reduction in investment in long-term assets.
CKD Bio Corp faces a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company's dilution risk is low, with no significant dilution potential from basic shares outstanding.
Recent events and filings for CKD Bio Corp include no disclosed material events or regulatory actions. The company's financial statements and disclosures do not indicate any recent significant developments that would impact its financial position or strategic direction.
- CKD Bio Corp has a market price of 17,930 KRW and a market capitalization of 98,363,244,870 KRW, with a price-to-earnings ratio of 34.74 and a price-to-book ratio of 0.78.
- The company's liquidity position is characterized by a current ratio of 1.16 and a negative net cash position after subtracting total debt, indicating a medium liquidity risk.
- CKD Bio Corp's profitability metrics, including a return on equity of 2.25% and a return on assets of 0.95%, are below typical thresholds for pharmaceutical companies.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- CKD Bio Corp has a positive operating cash flow of 3,502,109,750 KRW and a free cash flow of 5,173,329,070 KRW, indicating a positive cash flow generation capability.
- The company faces a medium liquidity risk and a low dilution risk, with no significant dilution potential from basic shares outstanding.
Bull / Bear case
Generated · model-assistedCash conversion ratio of 1.24 surpasses the cohort median of 0.95, suggesting effective translation of earnings into cash.
Revenue CAGR of 0.6% over four years indicates stable top-line performance despite recent annual volatility.
Latest fiscal year generated positive operating income of 3.6 billion KRW, marking a return to operational profitability.
Debt-to-equity ratio of 1.18 places the company in the bottom quartile, signaling significantly higher leverage risk than peers.
High credit risk flag suggests potential difficulties in meeting financial obligations or securing favorable financing terms.
In focus — financials by report
Revenue KRW 156.04B, +9,7% YoY; Operating income −26,5% YoY.
- ▍Revenue KRW 156.04B, +9,7% YoY
- ▍Operating income −26,5% YoY
- ▍Net income −154,0% YoY
- ▍Free cash flow +42,6% YoY
- ▍Net margin -10.7%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- CKD Bio Corp Market data — financials · 2026-05-26